Clinical Application of a Combination Therapy of Percutaneous Radiofrequency and Transcatheter Arterial Chemoembolization in Large Hepatic Tumors

沈理,陈敏华,严昆,杨薇,高文,廖盛日,杨仁杰
DOI: https://doi.org/10.3760/j.issn:1004-4477.2004.08.004
2004-01-01
Abstract:Objective To investigate the clinical role of a combination therapy of percutaneous radiofrequency ablation(RFA) and transcatheter arterial chemoembolization(TACE) in large hepatic tumors. Methods Out of 62 patients with hepatocellular carcinomas confirmed by pathology, 21 patients received a combination therapy of TACE and RFA(combination group), 22 patients TACE therapy alone, and the rest 19 patients RFA therapy alone. A total of 106 tumors with a mean diameter of ( 5.9± 0.7) cm(ranged from 5.0 to 8.1 cm) were detected, and the largest tumor was selected for observation in a patient with multiple lesions. There was no significant difference in mean age, tumor size and liver function grade among the three groups.Results Tumor complete necrosis accounted for 80.9%in combination group, which was significantly higher than that of TACE group and RFA group ( 27.2%, 47.4%,P 0.05). Tumor local recurrence was 23.8%, 45.5%, and 36.8% respectively in the combination group, TACE group, and RFA group, and there was no significant difference among the three groups(P 0.05). Mean survival duration of combination group was 25.6 months, significantly higher than that of TACE group( 14.9 months)(P 0.05), and similar to that of RFA group( 20.1 months)(P0.05). Conclusions Compared with TACE or RFA therapy alone, the combination therapy improves tumor complete necrosis rate and prolongs the patients′ survival duration.
What problem does this paper attempt to address?